Search

Your search keyword '"Hou, Yi-Feng"' showing total 20 results
Start Over Author "Hou, Yi-Feng" Publisher american association for cancer research (aacr)
20 results on '"Hou, Yi-Feng"'

2. Supplementary Figure from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial

Author

Chen, Li, primary, Jiang, Yi-Zhou, primary, Wu, Song-Yang, primary, Wu, Jiong, primary, Di, Gen-Hong, primary, Liu, Guang-Yu, primary, Yu, Ke-Da, primary, Fan, Lei, primary, Li, Jun-Jie, primary, Hou, Yi-Feng, primary, Hu, Zhen, primary, Chen, Can-Ming, primary, Huang, Xiao-Yan, primary, Cao, A-Yong, primary, Hu, Xin, primary, Zhao, Shen, primary, Ma, Xiao-Yan, primary, Xu, Ying, primary, Sun, Xiang-Jie, primary, Chai, Wen-Jun, primary, Guo, Xiaomao, primary, Chen, Xizi, primary, Xu, Yanhui, primary, Zhu, Xiao-Yu, primary, Zou, Jian-Jun, primary, Yang, Wen-Tao, primary, Wang, Zhong-Hua, primary, and Shao, Zhi-Ming, primary

Published
2023
Full Text
View/download PDF

4. Supplementary Figure from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial

Author

Chen, Li, primary, Jiang, Yi-Zhou, primary, Wu, Song-Yang, primary, Wu, Jiong, primary, Di, Gen-Hong, primary, Liu, Guang-Yu, primary, Yu, Ke-Da, primary, Fan, Lei, primary, Li, Jun-Jie, primary, Hou, Yi-Feng, primary, Hu, Zhen, primary, Chen, Can-Ming, primary, Huang, Xiao-Yan, primary, Cao, A-Yong, primary, Hu, Xin, primary, Zhao, Shen, primary, Ma, Xiao-Yan, primary, Xu, Ying, primary, Sun, Xiang-Jie, primary, Chai, Wen-Jun, primary, Guo, Xiaomao, primary, Chen, Xizi, primary, Xu, Yanhui, primary, Zhu, Xiao-Yu, primary, Zou, Jian-Jun, primary, Yang, Wen-Tao, primary, Wang, Zhong-Hua, primary, and Shao, Zhi-Ming, primary

Published
2023
Full Text
View/download PDF

7. Supplementary Figure from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial

Author

Chen, Li, primary, Jiang, Yi-Zhou, primary, Wu, Song-Yang, primary, Wu, Jiong, primary, Di, Gen-Hong, primary, Liu, Guang-Yu, primary, Yu, Ke-Da, primary, Fan, Lei, primary, Li, Jun-Jie, primary, Hou, Yi-Feng, primary, Hu, Zhen, primary, Chen, Can-Ming, primary, Huang, Xiao-Yan, primary, Cao, A-Yong, primary, Hu, Xin, primary, Zhao, Shen, primary, Ma, Xiao-Yan, primary, Xu, Ying, primary, Sun, Xiang-Jie, primary, Chai, Wen-Jun, primary, Guo, Xiaomao, primary, Chen, Xizi, primary, Xu, Yanhui, primary, Zhu, Xiao-Yu, primary, Zou, Jian-Jun, primary, Yang, Wen-Tao, primary, Wang, Zhong-Hua, primary, and Shao, Zhi-Ming, primary

Published
2023
Full Text
View/download PDF

8. Supplementary Figure from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial

Author

Chen, Li, primary, Jiang, Yi-Zhou, primary, Wu, Song-Yang, primary, Wu, Jiong, primary, Di, Gen-Hong, primary, Liu, Guang-Yu, primary, Yu, Ke-Da, primary, Fan, Lei, primary, Li, Jun-Jie, primary, Hou, Yi-Feng, primary, Hu, Zhen, primary, Chen, Can-Ming, primary, Huang, Xiao-Yan, primary, Cao, A-Yong, primary, Hu, Xin, primary, Zhao, Shen, primary, Ma, Xiao-Yan, primary, Xu, Ying, primary, Sun, Xiang-Jie, primary, Chai, Wen-Jun, primary, Guo, Xiaomao, primary, Chen, Xizi, primary, Xu, Yanhui, primary, Zhu, Xiao-Yu, primary, Zou, Jian-Jun, primary, Yang, Wen-Tao, primary, Wang, Zhong-Hua, primary, and Shao, Zhi-Ming, primary

Published
2023
Full Text
View/download PDF

10. Supplementary Figure from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial

Author

Chen, Li, primary, Jiang, Yi-Zhou, primary, Wu, Song-Yang, primary, Wu, Jiong, primary, Di, Gen-Hong, primary, Liu, Guang-Yu, primary, Yu, Ke-Da, primary, Fan, Lei, primary, Li, Jun-Jie, primary, Hou, Yi-Feng, primary, Hu, Zhen, primary, Chen, Can-Ming, primary, Huang, Xiao-Yan, primary, Cao, A-Yong, primary, Hu, Xin, primary, Zhao, Shen, primary, Ma, Xiao-Yan, primary, Xu, Ying, primary, Sun, Xiang-Jie, primary, Chai, Wen-Jun, primary, Guo, Xiaomao, primary, Chen, Xizi, primary, Xu, Yanhui, primary, Zhu, Xiao-Yu, primary, Zou, Jian-Jun, primary, Yang, Wen-Tao, primary, Wang, Zhong-Hua, primary, and Shao, Zhi-Ming, primary

Published
2023
Full Text
View/download PDF

14. Supplementary Figure from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial

Author

Chen, Li, primary, Jiang, Yi-Zhou, primary, Wu, Song-Yang, primary, Wu, Jiong, primary, Di, Gen-Hong, primary, Liu, Guang-Yu, primary, Yu, Ke-Da, primary, Fan, Lei, primary, Li, Jun-Jie, primary, Hou, Yi-Feng, primary, Hu, Zhen, primary, Chen, Can-Ming, primary, Huang, Xiao-Yan, primary, Cao, A-Yong, primary, Hu, Xin, primary, Zhao, Shen, primary, Ma, Xiao-Yan, primary, Xu, Ying, primary, Sun, Xiang-Jie, primary, Chai, Wen-Jun, primary, Guo, Xiaomao, primary, Chen, Xizi, primary, Xu, Yanhui, primary, Zhu, Xiao-Yu, primary, Zou, Jian-Jun, primary, Yang, Wen-Tao, primary, Wang, Zhong-Hua, primary, and Shao, Zhi-Ming, primary

Published
2023
Full Text
View/download PDF

19. Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial

Author

Chen, Li, primary, Jiang, Yi-Zhou, additional, Wu, Song-Yang, additional, Wu, Jiong, additional, Di, Gen-Hong, additional, Liu, Guang-Yu, additional, Yu, Ke-Da, additional, Fan, Lei, additional, Li, Jun-Jie, additional, Hou, Yi-Feng, additional, Hu, Zhen, additional, Chen, Can-Ming, additional, Huang, Xiao-Yan, additional, Cao, A-Yong, additional, Hu, Xin, additional, Zhao, Shen, additional, Ma, Xiao-Yan, additional, Xu, Ying, additional, Sun, Xiang-Jie, additional, Chai, Wen-Jun, additional, Guo, Xiaomao, additional, Chen, Xizi, additional, Xu, Yanhui, additional, Zhu, Xiao-Yu, additional, Zou, Jian-Jun, additional, Yang, Wen-Tao, additional, Wang, Zhong-Hua, additional, and Shao, Zhi-Ming, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results